Dr. Khong on Endocrine Combinations in ER+/HER2- Breast Cancer

ALTERNATE: neoadjuvant endocrine treatment in ER+/HER2- breast cancerПодробнее

Dr. Hershman on the Use of Endocrine Therapy in Premenopausal HR+/HER2- Breast CancerПодробнее

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancerПодробнее

Dr. Khong on the Benefit of Neoadjuvant Endocrine Therapy in ER+ Breast CancersПодробнее

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancerПодробнее

Dr. Yardley on Endocrine Therapy Plus CDK4/6 Inhibitors in Breast Cancer With Visceral MetastasesПодробнее

Neoadjuvant Endocrine Therapy in Breast CancerПодробнее

Dr. Denduluri on Treatment for ER+/HER2- Breast CancerПодробнее

Palbociclib, pembrolizumab, and endocrine therapy in HR+/HER2- breast cancerПодробнее

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment StrategiesПодробнее

Picking the right CDK 4/6 inhibitor upfront for metastatic breast cancer.Подробнее

Dr. Callahan on Endocrine Therapy in Patients With ER-Positive Breast CancerПодробнее

Expanding Treatment Options in ER+/HER2- Breast Cancer: SERDs, SERMs, SERCAs, and MoreПодробнее

Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNAПодробнее

Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast CancerПодробнее

Dr. Ellis on Neoadjuvant Endocrine Therapy for Breast CancerПодробнее

Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Breast CancerПодробнее

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast CancerПодробнее